Market Dynamics:

Rising prevalence of hereditary angioedema is a major driver of growth of the plasma protease C1-inhibitor treatment market. According to Angioedema Foundation, HAE affects approximately 1 in 10,000 to 1 in 50,000 people worldwide. Symptomatic treatments are very important for HAE patients as swollen larynx can potentially lead to asphyxiation if not treated on time. Plasma protease C1-inhibitor treatment addresses this unmet need by preventing onset of HAE attacks. Additionally, the approval and launch of newer plasma protease C1-inhibitor treatment drugs and treatment options by leading manufacturers is also fueling revenue growth of this market.

Key Takeaways

The Global Plasma Protease C1-Inhibitor Treatment Market Size  is expected to witness high growth. The global plasma protease C1-inhibitor treatment market is estimated to be valued at US$ 5432.28 Mn in 2023 and is expected to exhibit a CAGR of 18% over the forecast period 2023 to 2030.

The North America region currently dominates the global Plasma Protease C1-inhibitor Treatment Market owing to growing prevalence of hereditary angioedema, strong healthcare infrastructure and availability of advanced treatment options in countries like the US. Europe is the second largest market driven by rising patient awareness regarding hereditary angioedema in countries like Germany, UK, France. The Asia Pacific region is anticipated to be the fastest growing market over the forecast period supported by expanding healthcare sector, growing spending on orphan and rare disease treatment in China, India.

Key players
Key players operating in the Plasma Protease C1-inhibitor Treatment market are CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc. CSL Behring LLC dominates the market with its flagship treatment Berinert approved for treatment and prevention of hereditary angioedema attacks. Takeda Pharmaceutical Company Limited's Takhzyro enjoys strong demand as a long-acting prophylaxis treatment.

Explore more information on this topic, Please visit-     
https://click4r.com/posts/g/13812055/